Medincell successfully completes its Global Offer of 42.9 million euros

Medincell, a pharmaceutical technology company, has raised €42.9 million in its Global Offering. The fundraising will expand its BEPO® technology to new applications and strengthen the company’s balance sheet. The participation involved international healthcare investors such as Adage Capital Partners and Wellington Management.

The transaction was carried out without preferential subscription rights, split between a Private Placement and a public offering via PrimaryBid in France. 3,300,000 new shares were issued at €13 each, with a discount of approximately 7%. Following this issue, Medincell's share capital sees its structure slightly modified.

The settlement-delivery of the shares is scheduled for February 21, 2025 on Euronext Paris. The company and its management have signed a 90-day lock-up commitment, ensuring temporary stability in the fluctuation of the shareholding.